REG - Aptamer Group PLC - AGM Statement

AptamerAnnouncement

29/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241129:nRSc1007Oa&default-theme=true

RNS Number : 1007O  Aptamer Group PLC  29 November 2024

 

29 November 2024

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

Annual General Meeting Statement

Aptamer Group plc (AIM: APTA), the developer of novel Optimer(®) binders to
enable innovation in the life sciences industry, will hold its Annual General
Meeting (AGM) at 10:00 am today at the offices of Aptamer Group, Windmill
House, Innovation Way, York, YO10 5BR.

Dr Adam Hargreaves, Non-Executive Chairman will provide the following
statement:

"I am delighted with the progress made by Aptamer Group. Since the fundraising
of £2.6m in July this year, we have met our cost-base reduction targets,
streamlined our scientific production capabilities, and executed our new
commercial growth strategy to deliver optimised products of high quality to
our growing customer base.

Attracting new partners has ensured that we are now working with the majority
of the larger global pharmaceutical companies, alongside a wealth of
diagnostic, healthcare, and niche biotech partners. Particular highlights have
included the development of a vertical market platform in fibrosis, in which
we are working with AstraZeneca; the progression toward human trials of our
deodorant Optimer product with Unilever; and the successful production of an
Optimer delivery conjugate to an undisclosed genetic medicines company, with
which they are planning pre-clinical trials.

Our increased commercial traction has secured newly signed contracts,
currently up to the value of £471,000, which will ensure that the Group's
cash runway remains generous, allowing any licensing opportunities to evolve
and potentially crystalise over this extended period.

The Board looks forward to updating shareholders on further progress in due
course."

The AGM will provide no new material information. Results of the AGM will be
announced to the London Stock Exchange and placed on the Group's website, in
the usual way, as soon as practicable after the conclusion of the AGM.

- Ends -

 

For further information, please contact:

 

 Aptamer Group plc                                            +44 (0) 1904 217 404

 Arron Tolley, Chief Executive Officer
 SPARK Advisory Partners Limited - Nominated Adviser          +44 (0) 20 3368 3550

 Andrew Emmott / Adam Dawes
 Turner Pope Investments (TPI) Limited - Broker               +44 (0) 20 3657 0050

 James Pope / Andrew Thacker
 NorthStar Communications Limited - Investor Relations        +44 (0) 113 730 3896

 Sarah Hollins

 

About Aptamer Group plc

 

Aptamer Group  develops custom affinity binders through its proprietary
Optimer(®) platform to enable new approaches in therapeutics, diagnostics,
and research applications. The Company strives to deliver transformational
solutions that meet the needs of life science researchers and
developers. Optimer binders are oligonucleotide affinity ligands that can
function as an antibody alternative. The global affinity ligand market is
currently worth over $170 billion.

 

Aptamer has successfully delivered projects for a range of global pharma
companies, diagnostic development companies, and research institutes, covering
multiple application areas with the objective of establishing royalty-bearing
licenses.

 

To register for news alerts by email go to
https://aptamergroup.com/investors/investor-news-email-alerts/
(https://aptamergroup.com/investors/investor-news-email-alerts/) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGMBPBLTMTJTBJI